This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON)

Tipranks - Tipranks - Sat May 9, 3:24PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON) and Warby Parker (WRBY) with bullish sentiments.

Claim 55% Off TipRanks

Zevra Therapeutics (ZVRA)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Zevra Therapeutics, with a price target of $25.00. The company’s shares closed last Friday at $11.13.

According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -13.2% and a 33.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, SELLAS Life Sciences Group, and OS Therapies Incorporated. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zevra Therapeutics with a $24.00 average price target, implying an 115.4% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $24.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

CG Oncology, Inc. (CGON)

JonesTrading analyst Boris Peaker maintained a Buy rating on CG Oncology, Inc. on May 5 and set a price target of $85.00. The company’s shares closed last Friday at $69.62.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 19.6% and a 45.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Janux Therapeutics Inc, and Oric Pharmaceuticals. ;'>

CG Oncology, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $88.58, which is a 28.6% upside from current levels. In a report issued on April 27, RBC Capital also maintained a Buy rating on the stock with a $79.00 price target.

Warby Parker (WRBY)

In a report released today, Oliver Chen from TD Cowen maintained a Buy rating on Warby Parker, with a price target of $32.00. The company’s shares closed last Friday at $29.54.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.4% and a 49.6% success rate. Chen covers the NA sector, focusing on stocks such as Canada Goose Holdings, Brilliant Earth Group, and Ermenegildo Zegna. ;'>

Warby Parker has an analyst consensus of Moderate Buy, with a price target consensus of $29.11, a 7.5% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $31.00 price target.

Read More on ZVRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).